✦ LIBER ✦

Clinical management of BRCA1 and BRCA2 mutation carriers

✍ Scribed by Domchek, S M; Weber, B L

Book ID: 110071889
Publisher: Nature Publishing Group
Year: 2006
Tongue: English
Weight: 136 KB
Volume: 25
Category: Article
ISSN: 0950-9232
DOI: 10.1038/sj.onc.1209881

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Screening and Clinical Implications for

Screening and Clinical Implications for BRCA1 and BRCA2 Mutation Carriers

✍ Sharon E. Plon 📂 Article 📅 1998 🏛 Springer US 🌐 English ⚖ 191 KB

Clinical management of women with genomi

Clinical management of women with genomic BRCA1 and BRCA2 mutations*

✍ Jenny Chang; Richard M. Elledge 📂 Article 📅 2001 🏛 Springer US 🌐 English ⚖ 155 KB

Risk of ipsilateral breast cancer in BRC

Risk of ipsilateral breast cancer in BRCA1 and BRCA2 mutation carriers

✍ Kelly Metcalfe; Henry T. Lynch; Parviz Ghadirian; Nadine Tung; Charmaine Kim-Sin 📂 Article 📅 2011 🏛 Springer US 🌐 English ⚖ 195 KB

Predictors of contralateral breast cance

Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers

✍ Metcalfe, K; Gershman, S; Lynch, H T; Ghadirian, P; Tung, N; Kim-Sing, C; Olopad 📂 Article 📅 2011 🏛 Nature Publishing Group 🌐 English ⚖ 345 KB

Clinical management of BRCA1- and BRCA2-

Clinical management of BRCA1- and BRCA2-associated breast cancer

✍ Stephen E. Karp 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 115 KB 👁 2 views

The recent discovery of the breast cancer-associated genes BRCA1 and BRCA2 has changed the clinical care provided to women at high risk of breast cancer. We will review what is currently known about the clinical management of patients who bear (or are suspected of bearing) mutations in either of the

BRCA1 and BRCA2 mutation carriers as pot

BRCA1 and BRCA2 mutation carriers as potential candidates for chemoprevention trials

✍ Ephrat Levy-Lahad; Michal Krieger; Orit Gottfeld; Paul Renbaum; Gaya Klein; Shlo 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 69 KB

The identification of cancer susceptibility genes offers new avenues for selecting high-risk individuals as subjects for chemoprevention trials. Because carriers of predisposing mutations are at high risk, they are more likely to enroll and comply with chemoprevention trials, and meaningful results